<DOC>
	<DOCNO>NCT00258427</DOCNO>
	<brief_summary>RATIONALE : A bone marrow umbilical cord blood transplant may able replace blood-forming cell destroy chemotherapy . Giving combination chemotherapy donor stem cell transplant may make transplant likely work . This may effective treatment patient high risk Fanconi 's anemia . PURPOSE : This clinical trial study well combination chemotherapy work treat high risk patient undergo donor stem cell transplant Fanconi 's anemia .</brief_summary>
	<brief_title>Hematopoietic Stem Cell Transplantation High Risk Patients With Fanconi Anemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether incidence neutrophil engraftment acceptable high-risk patient Fanconi 's anemia treat busulfan , cyclophosphamide , fludarabine , antithymocyte globulin follow allogeneic hematopoietic stem cell transplantation . Secondary - Determine tolerability mycophenolate mofetil patient . - Determine incidence acute chronic graft-vs-host disease patient treat regimen . - Determine incidence major infection patient history major infection treat regimen . - Determine incidence relapse patient refractory anemia excess blast , refractory anemia excess blast transformation , acute myeloid leukemia treat regimen - Determine probability 1-year survival patient treat regimen . OUTLINE : Patients stratify accord donor/recipient HLA type ( identical v ) . - Cytoreductive combination chemotherapy : Patients receive busulfan intravenously ( IV ) 2 hour twice daily day -7 -6 cyclophosphamide IV 2 hour fludarabine IV 30 minute daily day -5 -2 . - Graft failure prophylaxis : Patients receive methylprednisolone IV twice daily day -5 30 anti-thymocyte globulin IV 4-6 hour twice daily day -5 -1 . - Graft-vs-host disease prophylaxis : Patients receive cyclosporine IV 2 hour twice daily day -3 100 ( patient match sibling donor ) day -3 180 ( patient another donor type ) . Patients also receive mycophenolate mofetil orally IV twice daily day -3 45 . - Allogeneic hematopoietic stem cell transplantation ( HSCT ) : Patients undergo allogeneic HSCT ( use bone marrow umbilical cord blood ) day 0 . Patients receive filgrastim ( G-CSF ) subcutaneously begin day 1 continue blood count recover . After completion study treatment , patient follow periodically 3 year .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients must &lt; 45 year age diagnosis Fanconi anemia : Biallelic BRCA2 mutation , Aplastic anemia , advance myelodysplastic syndrome ( MDS ) ( MDS â‰¥5 % blast ) , acute leukemia ineligible total body irradiation . Aplastic anemia define least one follow ( without cytogenetic abnormality ) : platelet count &lt; 20 * 10^9 , absolute neutrophil count ( ANC ) &lt; 5 * 10^8/L , Hgb &lt; 8 g/dL / Patients must HLAA , B , DRB1 identical 1 antigen mismatch related unrelated BM donor HLAA , B , DRB1 identical , 1 antigen 2 antigen mismatch related unrelated umbilical cord blood ( UCB ) donor . Patients donor type HLAA B use serological level type DRB1 use high resolution molecular typing . Adequate major organ function include : Cardiac : ejection fraction &gt; 45 % Hepatic : clinical evidence hepatic failure ( e.g . coagulopathy , ascites , cirrhosis ) Karnofsky performance status &gt; 70 % Lansky &gt; 50 % Women child bear potential must use adequate birth control negative pregnancy test . Active CNS leukemia time HSCT . Active uncontrolled infection within one week hematopoietic stem cell transplant ( HSCT ) . Pregnant lactate female . Donor Donor must good health base review system result physical examination . Donor must normal hemoglobin , white count , platelet count partial thromboplastin time ( PTT ) , negative diepoxybutane ( DEB ) test . HIVNAT negative , HTLV1 , HTLV2 negative , Hepatitis B C negative . Female donor childbearing potential must negative pregnancy test . Unrelated donor must agree peripheral blood stem cell ( PBSC ) donation Donor Donor lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Fanconi anemia</keyword>
</DOC>